Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes – [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience – do we need [18F]FDG

Introduction: Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). The aim of the study was the evaluation of the role of [ 18 F]FDG PET/CT in predicting response, progression-free survival (PFS) and overall survival (OS) after tandem therapy [ 90 Y]Y/[ 177 Lu]Lu-DOTATATE. Material and methods: Seventy-five patients with...